Denis Claude Roy
Office Phone: 514-252-3400 ext. 3331
Lab Phone: 514-252-3400 # 4663/4650
Research Axis Immunology-Oncology
Research Unit Cellular Therapy
- Director, Cellular Therapy Laboratory
- Scientific Director, CRHMR
- Full Professor at the University of Montreal
- Postdoctoral Fellowship in Tumor Immunology, Harvard University (at the Dana-Farber Cancer Institute)
- FRCPC, Hematology, University of Montreal
- M.D., University of Montreal.
- Immunology of leukemia and lymphoma: translational research;
- Autologous and allogenous hematopoietic stem cell transplantation;
- Manipulation of hematopoietic cell grafts: selective elimination of alloreactive T lymphocytes to prevent and treat graft-versus-host diseases;
- Specific targeting of malignant cells, using photodynamic and immunological therapy approaches;
- Study of action mechanisms and optimization of monoclonal antibody and immunoconjugates;
- Growth and expansion factors of hematopoietic stem cells and blood progenitors.
The aim of our study is to use cellular and immunological approaches to fight such blood cancers as leukemia and lymphoma. Our research unit is examining different monoclonal antibodies and immunoconjugates as well as a photodynamic approach for eliminating cancerous and alloreactive cells.
We have developed particular expertise in translational research, enabling the transfer of basic discoveries to patients. Thanks to our studies, new hematological and immunological strategies have been identified and were implemented in early clinical studies (Phase 1 and 2). We are the principal investigator of a multicentric study (Canada and USA) to evaluate a new photodynamic treatment.
We are also working on the expansion of hematopoietic stem cells and blood cell progenitors that will enable and accelerate hematological and immunological reconstitution following transplantation.
Research Laboratory Coordinator
- Vibhuti Dave
- Radia Sidi Boumedine
- Marie-Pier Giard
- Fannie Larochelle
- Isabelle Savoie-Rondeau
- Jessica Trottier
- José Kitenge
- Jean-Philippe Bastien
- Vanessa Laflamme
- Renaud Mnuguerra-Gagné
Sidi Boumédine, R., Roy, D.C. Elimination of Alloreactive T Cells Using Photodynamic Therapy. Cytotherapy, 2005, 7: 134-143.
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Balser, B.W., Liu, S., Mao, H., Chang, J.S., Galietta, A., Uttam, A., Roy, D.C., Valtieri, M., Bruner-Klisovic, R., Caligiuri, M.A., Bloomfield, C.D., Marcucci, G., Perrotti, D. The Tumor Suppressor PP2A is Functionally Inactivated in Blast Crisis CML Through the Inhibitory Activity of the BCR/ABL-Regulated SET Protein. Cancer Cell, 2005, 5: 355-68.
Notari, M., Neviani, P., Santhanam, R., Bradley, B.W., Chang, J.S., Galietta, A., Willis, E., Roy, D.C., Caligiuri, M.A., Marcucci, G., Perrotti, D. A MAPK/HNRPK Pathway Controls BCR/ABL Oncogenic Potential by Regulating MYC mRNA translation. Blood, 2006, 107:2507-16.
Kelly, M., Roy, D.C., Labbe, A.C., Laverdière, M. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria? Bone Marrow Transplantation, 2006, 38 :183-8.
Allan, D., Dubé, P., Roy, J., Roy, D.C. Endothelial-like vascular progenitor cells from autologous and allogeneic donnors: mobilization features distinct from hematopoietic progenitors. Biology of Blood and Marrow Transplantation, 2007 13:433-439.
Neviani, P., Santhanam, R., Oaks, J.J., Elring, A.M., Notari, M., Blaser, B.W., Liu, S, Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., Druker, B.J., Cortes, J., Marcucci, G., Chen, C.S., Verrills, N.M., Roy, D.C., Caligiuri, M.A., Bloomfield, C., Byrd, J.C., Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clinical Investigation, 2007, 117(9): 2408-2421.
Labbe, A.C., Su, S.H., Laverdiere, M., Pepin, J., Patino, C., Cohen, S., Kiss, T., Lachance, S., Sauvageau, G., Busque, L, Roy, D.C., Roy, J. High Incidence of Invasive Aspergillosis Associated with Intestinal Graft-versus-Host Disease following Nonmyeloablative Transplantation. Biol. Blood Marrow Transplantation, 2007, 13(10): 1192-1200.
Chang, J.S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A.M., Briercheck, E., Ronchetti, M., Roy, D.C., Calabretta, B., Caligiuri, M.A., Perrotti, D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood, 2007, 110(3): 994-1003.
Baron, C., Somogyi, R., Greller, L.D., Rineau, V., Wilkinson, P., Cho, C.R., Cameron, M.J., Kelvin, D.J., Chagnon, P., Roy, D.C., Busque, L., Sekaly, R.P., Perreault, C. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Medicine, 2007, 4; (e23): 69-83.
Bradstock, K., Roy, D.C.: Tumor Cell Purging in Autologous Hematopoietic Stem Cell Transplantation in Champlin, R., Brenner, M., Ritz, J., Fibbe, W., Ljungman, P. (Eds): Clinical Bone Marrow and Blood Stem Cell Transplantation, Cambridge University Press, 2004, p. 262-276.
DISTINCTIONS AND ACHIEVEMENTS
- Patents (4).
Dr. Roy is member on the NCIC Executive Committee for Blood Cancers.
- Fonds de la Recherche en Santé du Québec (FRSQ)
- Canadian Institutes of Health Research (CIHR)
- Canadian Foundation for Innovation (CFI), and our industry partners.